Your browser doesn't support javascript.
loading
Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Rochau, Ursula; Sroczynski, Gaby; Wolf, Dominik; Schmidt, Stefan; Jahn, Beate; Kluibenschaedl, Martina; Conrads-Frank, Annette; Stenehjem, David; Brixner, Diana; Radich, Jerald; Gastl, Günther; Siebert, Uwe.
Afiliação
  • Rochau U; a Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health and Health Technology Assessment , UMIT - University for Health Sciences, Medical Informatics and Technology , Hall in Tirol , Austria.
  • Sroczynski G; b Area 4: Health Technology Assessment and Bioinformatics, ONCOTYROL - Center for Personalized Cancer Medicine , Innsbruck , Austria.
  • Wolf D; a Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health and Health Technology Assessment , UMIT - University for Health Sciences, Medical Informatics and Technology , Hall in Tirol , Austria.
  • Schmidt S; c Hematology and Oncology, Internal Medicine V, Medical University Innsbruck , Austria.
  • Jahn B; d Oncology, Hematology and Rheumatology, Medical Clinic III, University Clinic Bonn (UKB) , Germany.
  • Kluibenschaedl M; c Hematology and Oncology, Internal Medicine V, Medical University Innsbruck , Austria.
  • Conrads-Frank A; a Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health and Health Technology Assessment , UMIT - University for Health Sciences, Medical Informatics and Technology , Hall in Tirol , Austria.
  • Stenehjem D; a Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health and Health Technology Assessment , UMIT - University for Health Sciences, Medical Informatics and Technology , Hall in Tirol , Austria.
  • Brixner D; a Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health and Health Technology Assessment , UMIT - University for Health Sciences, Medical Informatics and Technology , Hall in Tirol , Austria.
  • Radich J; e Department of Pharmacotherapy and Program in Personalized Health Care , University of Utah , Salt Lake City , UT , USA.
  • Gastl G; f Huntsman Cancer Institute, University of Utah Hospitals and Clinics , Salt Lake City , UT , USA.
  • Siebert U; a Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health and Health Technology Assessment , UMIT - University for Health Sciences, Medical Informatics and Technology , Hall in Tirol , Austria.
Leuk Lymphoma ; 56(8): 2315-25, 2015.
Article em En | MEDLINE | ID: mdl-25393806
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Temas: ECOS / Aspectos_gerais / Financiamentos_gastos Bases de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Análise Custo-Benefício / Inibidores de Proteínas Quinases / Antineoplásicos Tipo de estudo: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Limite: Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: Leuk Lymphoma Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Áustria
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Temas: ECOS / Aspectos_gerais / Financiamentos_gastos Bases de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Análise Custo-Benefício / Inibidores de Proteínas Quinases / Antineoplásicos Tipo de estudo: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Limite: Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: Leuk Lymphoma Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Áustria